What are the clinical significances of abnormally elevated D-dimer? Let's explore this topic today.
I. Application of D-dimer in Deep Vein Thrombosis (DVT)
The overall diagnostic value of D-dimer in Deep Vein Thrombosis (DVT) is similar to its value in Pulmonary Embolism (PE): A negative D-dimer result can essentially rule out the possibility of DVT; a positive result has limited significance (due to insufficient specificity, as many conditions can cause elevated D-dimer). The sensitivity of D-dimer in DVT diagnosis is 95%, specificity is 40%, positive predictive value is 48%, and negative predictive value is 95%.
Researchers like Jack Hirsh believe that a negative D-dimer can rule out the possibility of deep vein thrombosis. Combining it with venous ultrasound examination is safe and effective, and can significantly reduce the need for invasive ascending venography (once considered the gold standard for diagnosing DVT). Studies by Bounameaux H et al. confirmed that a single D-dimer test could rule out DVT in one-third of outpatients suspected of having the condition, thereby saving considerable medical costs and time.
II. The Relationship Between D-dimer and Malignant Tumors
A large body of literature indicates that tumors can cause elevated D-dimer concentrations in patients, and it can serve as a criterion for staging and prognosis. In one study, Masatoshi Oya et al. found that D-dimer levels in colorectal cancer patients were significantly higher than in patients with benign diseases, and preoperative D-dimer levels were positively correlated with tumor pathology results and stage.
Postoperative survival time was significantly shorter for patients with high preoperative D-dimer levels compared to those with low levels. Kong Rong et al. measured D-dimer in 128 patients with malignant tumors. The results showed: D-dimer levels in the initial-onset groups of acute leukemia, malignant lymphoma, and solid tumors were significantly higher than those in the control group, with significant differences (P<0.05). Levels during remission were significantly lower than during the initial onset (P<0.05); D-dimer levels in the malignant lymphoma group varied with different stages; levels in the solid tumor group with metastasis were significantly higher than in the group without metastasis, showing a significant difference (P<0.01).
Osamu Taguchi et al. divided all lung cancer patients into two groups based on the median D-dimer value of 150 ng/mL. The survival rate of the high D-dimer group was lower than that of the low D-dimer group, and this predictive factor was independent of tumor stage, histological type, and tumor size's impact on survival. It is speculated that the hypercoagulable state in cancer patients is related to tissue factor-dependent extrinsic pathways and non-tissue factor-related tumor procoagulant activity. The extrinsic pathway is thought to be activated by host monocytes or vascular endothelial cells. Non-tissue factor-related tumor procoagulant activity is believed to directly activate Factor X.
Activation of fibrinolysis by urokinase plasminogen activator (u-PA) is another characteristic of tumors. u-PA secreted by tumor stromal cells binds to u-PA receptors on tumor cell surfaces, not only activating plasminogen and causing fibrin degradation but also activating proteolytic enzymes, leading to matrix degradation at the tumor-host interface, facilitating tumor metastasis and invasion.
III. The Relationship Between D-dimer and Myocardial Infarction
In a clinical study by Yu Jun et al. in China, it was found that D-dimer levels in patients with Acute Myocardial Infarction (AMI) were significantly higher than those in the normal control group (P<0.01). After thrombolysis with urokinase, D-dimer levels in the AMI group decreased after 48 hours.
A study by Ridker PM et al. found that D-dimer is closely related to ischemic heart disease, with the incidence of the latter increasing as D-dimer concentrations rise (P<0.01). Elevated D-dimer predicts a higher future risk of myocardial infarction but is not an independent predictor.
IV. The Relationship Between D-dimer and Cerebral Infarction
In a study by Berge et al., it was found that D-dimer levels are linearly correlated with the severity of cerebral infarction, and can be used to assess the prognosis of stroke patients, both at admission and after discharge. Fattori B et al. found that D-dimer also increases in unilateral vestibular paralysis. Research by Liu Qiang et al. in China found that patients with higher plasma D-dimer levels have a relatively higher risk of recurrent cerebral infarction.
V. The Relationship Between D-dimer and Liver Disease Detection
In liver diseases, plasma D-dimer levels are significantly increased and are positively correlated with the severity of the liver disease. Wilder et al. measured plasma D-dimer in 59 patients with acute and chronic liver disease, finding elevated levels to varying degrees in 48 of them.
Jin Guangrong et al. found that D-dimer levels in patients with various types of hepatitis were significantly higher than those in the control group, possibly related to impaired anticoagulation systems. Antiplasmins and Antithrombin III (AT-III) are synthesized by the liver. In liver disease, their synthesis decreases, leading to hyperfibrinolysis. Under the activation of plasmin, fibrin and fibrinogen are degraded, resulting in significantly increased degradation products like D-dimer.
Therefore, D-dimer concentration can serve as a marker for assessing the degree of liver damage.
VI. The Significance of D-dimer in Other Diseases
Many diseases can activate the body's coagulation and/or fibrinolytic systems, leading to elevated D-dimer levels. Furthermore, this activation is closely related to the disease stage, severity, and treatment status. Therefore, detecting D-dimer levels in these diseases can serve as a marker for disease staging, prognosis assessment, and treatment guidance.
6.1 The Relationship Between D-dimer and Thoracic Aortic Dissection
Thomas Weber conducted a prospective study on patients with acute chest pain. All patients diagnosed with thoracic aortic dissection had significantly elevated D-dimer levels. The degree of elevation was related to the time from symptom onset to lab testing and the size of the dissection, but not to patient prognosis.
6.2 The Relationship Between D-dimer and Systemic Lupus Erythematosus (SLE)
Research by Wang Fudang et al. in China found that plasma D-dimer levels in patients with active SLE were significantly higher than those in patients with stable SLE and healthy controls. D-dimer levels decreased significantly during the stable phase, and as the condition of patients in the active phase improved and stabilized, their plasma D-dimer levels gradually showed a downward trend. This may be related to the hypercoagulable state and fibrinolytic activation in active phase patients, leading to elevated D-dimer levels. This suggests that D-dimer can be an indicator of SLE disease activity and clinical efficacy.
6.3 The Relationship Between D-dimer and Kidney Disease Detection
In a study by Zhuge Hong et al. in China, plasma D-dimer and blood FDP levels were measured in 47 children with kidney disease and 15 healthy children. Dynamic monitoring was performed on 15 children with nephropathy before and after anticoagulant treatment. Results showed that blood D-dimer levels in children with different kidney diseases were higher than those in the normal group, with the increase being most significant in the nephropathy group (P<0.01). Dynamic monitoring results for the 15 children with nephropathy showed that blood D-dimer levels decreased and approached normal after anticoagulant treatment. The results suggest that in children with kidney disease without clinical manifestations of embolism, measuring D-dimer can indirectly predict the existence of a hypercoagulable state and can serve as a basis for anticoagulant therapy and prognosis estimation. D-dimer results indicated that levels in all three disease groups were higher than those in the healthy control group (P<0.05).
6.4 The Relationship Between D-dimer and Neonatal Asphyxia
In a study by Zhang Haiying et al. in China, it was found that umbilical cord blood D-dimer levels in the asphyxia group were significantly higher than those in the normal control group (P<0.01). Furthermore, umbilical cord blood D-dimer levels in the severe asphyxia group were significantly higher than those in the mild asphyxia group (P<0.01).
6.5 The Relationship Between D-dimer and Pulmonary Arterial Hypertension (PAH)
D-dimer testing is useful for evaluating patients with primary pulmonary arterial hypertension and helps identify high-risk patients. Shitrit et al. reported that plasma D-dimer levels were positively correlated with New York Heart Association (NYHA) functional class (P=0.01) and pulmonary artery pressure (P=0.03), and negatively correlated with arterial oxygen saturation (P=0.03) and 6-minute walk distance (P=0.04). One-year survival rate was also negatively correlated with plasma D-dimer levels (P=0.004); patients with higher plasma D-dimer levels had a poorer prognosis. Plasma D-dimer levels showed no correlation with gender, age, diffusing capacity for carbon monoxide (DLCO), or cardiac index.
6.6 The Relationship Between D-dimer and Disseminated Intravascular Coagulation (DIC)
A large amount of clinical practice has proven that D-dimer, as a marker of secondary hyperfibrinolysis, has good application value in the diagnosis and monitoring of DIC. DIC is a complex pathophysiological process and a severe acquired systemic thrombo-hemorrhagic syndrome.
It is characterized by an imbalance in the body's coagulation and anticoagulation mechanisms, leading to diffuse microvascular thrombosis and secondary hyperfibrinolysis. D-dimer levels increase in the early stages of DIC formation and can continue to rise more than 10-fold as the disease progresses.
Therefore, D-dimer can serve as a primary indicator for the early diagnosis and monitoring of DIC. Additionally, simultaneous measurement of D-dimer and FDP can greatly improve diagnostic efficiency.
6.7 The Role of D-dimer in Monitoring Thrombolytic Therapy
D-dimer can serve as a specific monitoring indicator for thrombolytic therapy in thrombotic diseases. During thrombolytic treatment, changes in D-dimer levels generally exhibit the following characteristics:
A significant short-term increase in D-dimer levels after thrombolysis, followed by a gradual decrease, suggests effective treatment.
If D-dimer levels continue to rise or decrease slowly after thrombolysis, it suggests an insufficient dosage of thrombolytic drugs.
Thrombolytic therapy should continue until D-dimer levels decrease to the normal range.
A return to normal D-dimer levels is an indication to stop thrombolysis. It should be noted that the timing of the D-dimer peak varies depending on the disease being treated with thrombolysis. In acute myocardial infarction and cerebral infarction, D-dimer peaks 1-6 hours after thrombolysis and returns to pre-treatment levels within 24 hours. However, in DVT thrombolysis, the D-dimer peak often occurs at 24 hours or later.
For patients with chronic DVT, D-dimer levels may be higher than normal before thrombolysis, but do not increase after thrombolysis, or rapidly decrease to the normal range. This indicates that only a small amount of fresh thrombus is present, with most being organized old thrombus, and thrombolysis may not achieve satisfactory results. Additionally, after completing thrombolytic therapy, D-dimer levels should be monitored periodically for some time to prevent thrombus recurrence.